News & Updates

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

11 Jun 2025

The addition of granulocyte colony-stimulating factor (GCSF) to prednisolone results in improved steroid responsiveness and prolonged survival with fewer infections and new-onset complications among patients with severe alcohol-associated hepatitis (SAH), a study has shown.

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

11 Jun 2025

Are statins protective against HCC?

10 Jun 2025 by

In a study presented at EASL 2025, the use of statins appears to be associated with a reduced risk of hepatocellular carcinoma (HCC) and slower progression of liver fibrosis in individuals with chronic liver disease (CLD).

Are statins protective against HCC?

10 Jun 2025

Efruxifermin misses mark in MASH-related compensated cirrhosis

10 Jun 2025

Treatment with the bivalent fibroblast growth factor 21 (FGF21) analogue efruxifermin falls short of improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction–associated steatohepatitis (MASH), according to a phase 2b study.

Efruxifermin misses mark in MASH-related compensated cirrhosis

10 Jun 2025

Efruxifermin reduces fibrosis in MASH cirrhosis

09 Jun 2025 by

The long-acting, bivalent fibroblast growth factor 21 analogue efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) in the phase 2b SYMMETRY trial.

Efruxifermin reduces fibrosis in MASH cirrhosis

09 Jun 2025

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

05 Jun 2025 by

A network meta-analysis (NMA) reports that the combination regimen comprising atezolizumab and bevacizumab appears to be better than other first-line systemic therapeutic alternatives for advanced hepatocellular carcinoma (HCC) in terms of providing a balance between overall survival (OS) benefit and quality of life (QoL) preservation.

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

05 Jun 2025

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025 by

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

04 Jun 2025

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025 by

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

30 May 2025

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025 by

Patients with chronic hepatitis B (CHB) in the indeterminate phase are predisposed to advanced liver disease and hepatocellular carcinoma (HCC), as shown by a systematic review and meta-analysis.

Antiviral therapy lowers HCC risk in indeterminate CHB phase

27 May 2025

News & Updates

Filter by Specialty:

Specialty:

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

GCSF plus prednisolone extends survival in severe alcohol-associated hepatitis

Are statins protective against HCC?

Are statins protective against HCC?

Efruxifermin misses mark in MASH-related compensated cirrhosis

Efruxifermin misses mark in MASH-related compensated cirrhosis

Efruxifermin reduces fibrosis in MASH cirrhosis

Efruxifermin reduces fibrosis in MASH cirrhosis

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

Atezolizumab-bevacizumab provides optimal balance between survival, QoL benefits in HCC

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

Elebsiran + PEG-IFN alfa combo ENSUREs higher HBsAg loss

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Antiviral therapy lowers HCC risk in indeterminate CHB phase

Antiviral therapy lowers HCC risk in indeterminate CHB phase